Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
soft tissue neoplasms
MeSH D012983 - soft tissue neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009371:
Neoplasms by site
0 Companies
0 Drugs
Success rate
D012983:
Soft tissue neoplasms
37 Companies
4 Drugs
$
Success rate
D019042:
Muscle neoplasms
0 Companies
0 Drugs
Success rate
D019043:
Vascular neoplasms
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
11
%
1/9
Phase 2
0
%
0/1
Phase 3
100
%
4/4
Approved:
4
Overall Success rate:
0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Docetaxel
,
Doxorubicin
,
Doxorubicin hydrochloride
Mylan
Docetaxel
Novartis
Pazopanib
Sanofi
Docetaxel
Pfizer
Docetaxel
,
Doxorubicin
,
Doxorubicin hydrochloride
Dr Reddys Laboratories
Doxorubicin
,
Doxorubicin hydrochloride
Bristol Myers Squibb
Doxorubicin
,
Doxorubicin hydrochloride
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use